Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare lymphoma study aims to unlock secrets of treatment success

NCT ID NCT07467317

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study will gather information from 100 people with a rare type of lymphoma called systemic anaplastic large cell lymphoma (sALCL) who have been treated with a drug combination called BV-CHP. Researchers want to see how well the treatment works in real life and understand why it works better for some people by studying their medical images and tumor samples. The goal is to find patterns that could help predict who will respond best to this therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient affected by systemic Anaplastic Large Cell Lymphoma treated as front line therapy with BV-CHP in clinical practice

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * Histological diagnosis of sALCL (ALK positive and ALK negative); * Have received BV-CHP as front-line therapy in real life setting; * Availability of histological material of initial ALCLs diagnosis: a FFPE block from an excisional/incisional biopsy must be provided for patient enrollment. FNAB and GNAB will not be considered for the study; * Signed written informed consent Exclusion Criteria: * Histological diagnosis other than sALCL; * Front line treatment other than BV-CHP; * Patients treated with BV-CHP in the contest of a clinical trial; * Refuse to sign a written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic large cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaplastic large cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. Ordine Mauriziano - S.C.D.U. Ematologia

    Torino, Italy

  • A.O.R.N. S. Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

    Avellino, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia

    Torino, Italy

  • A.S.L. di Pescara P.O. Santo Spirito - U.O.C. Ematologia

    Pescara, Italy

  • A.S.S.T Papa Giovanni XXIII - S.C. Ematologia

    Bergamo, Italy

  • A.S.S.T. Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

    Milan, Italy

  • A.S.S.T. Ovest Milanese Ospedale di Legnano - U.O.C. di Ematologia

    Legnano, Italy

  • A.S.S.T. Sette Laghi - S.C. Ematologia

    Varese, Italy

  • A.U.S.L. di Piacenza Osp. Guglielmo da Saliceto - U.O.C. Ematologia e Centro Trapianti

    Piacenza, Italy

  • I.R.C.C.S. A.O.U. di Bologna Policlinico S. Orsola - U.O. Ematologia

    Bologna, Italy

  • I.R.C.C.S. Centro di Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati

    Aviano, Italy

  • I.R.C.C.S. Fondazione Policlinico Universitario Gemelli - U.O.S.D. Malattie linfoproliferative extramidollari

    Roma, Italy

  • I.R.C.C.S. Istituto Europeo di Oncologia - U.O. Oncoematologia

    Milan, Italy

  • I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

    Bari, Italy

  • I.R.C.C.S. Istituto di Candiolo - FPO

    Candiolo, Italy

  • I.R.C.C.S. Ospedale San Raffaele - U.O. Ematologia e Trapianto di Midollo Osseo

    Milan, Italy

  • IRCCS Humanitas Research Hospital - U.O. Ematologia

    Rozzano, Italy

  • U.L.S.S. 2 Marca Trevigiana Osp. Ca' Foncello - U.O.C. Ematologia

    Treviso, Italy

  • U.L.S.S. 8 Berica - U.O.C. Ematologia

    Vicenza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.